Magnesium citrate is one of the more effective supplements for preventing calcium oxalate kidney stones, which account for about 80% of all kidney stones. It works through a dual mechanism: the magnesium and the citrate each independently reduce stone formation, making the combination particularly useful. Clinical trials show citrate salts can cut new stone formation by roughly 74% compared to placebo, and potassium-magnesium citrate specifically reduced stone risk by 80% in one controlled trial of 64 participants.
How Magnesium Citrate Prevents Stones
Magnesium citrate delivers two stone-fighting ingredients in a single supplement. Citrate binds to calcium in urine, preventing it from linking up with oxalate to form crystals. Magnesium does the same thing from a different angle: it competes with calcium for oxalate binding sites, so less calcium oxalate is available to crystallize. Together, they also lower the overall supersaturation of calcium oxalate in urine, meaning the conditions for crystal formation become less favorable in the first place.
Beyond blocking crystallization, citrate raises urinary pH, making urine less acidic. Acidic urine promotes both calcium oxalate and uric acid stone formation. In a three-year study of 247 patients with recurrent stones, potassium-magnesium citrate raised urinary pH from 5.62 to 6.87, a significant shift toward a more protective range. That same study showed urinary citrate levels nearly tripled, rising from about 222 mg/dL to 604 mg/dL within six months. Low urinary citrate is one of the most common metabolic abnormalities in people who form kidney stones, so correcting it addresses a root cause rather than just managing symptoms.
What the Clinical Evidence Shows
A Cochrane systematic review, the gold standard for medical evidence, pooled data from seven studies covering 324 participants and found that citrate salt therapy reduced new stone formation by 74% compared to no treatment or placebo. For the potassium-magnesium citrate subgroup specifically, the reduction was even more striking: an 80% lower risk of forming new stones.
The benefits go beyond prevention. Citrate therapy significantly reduced existing stone size in four studies of 160 participants and roughly doubled the likelihood that remaining stones stayed stable rather than growing. Patients on citrate therapy were also far less likely to need retreatment procedures. The Cochrane reviewers concluded that citrate salts prevent new stone formation and reduce further growth in patients whose stones predominantly contain oxalate.
In the three-year prospective study, stone recurrence rates dropped from an average of 3.23 episodes per patient per year to just 0.35. That’s roughly a tenfold reduction in stone events, which is meaningful for anyone who has experienced the pain of passing a stone.
Where It Fits in Official Guidelines
The American Urological Association recognizes potassium-magnesium citrate as an evidence-based therapy for reducing calcium stone risk. Their guidelines on medical management of kidney stones cite randomized controlled trials demonstrating its benefit, placing alkali citrate alongside high fluid intake as a proven preventive strategy. The AUA notes that potassium-magnesium citrate showed benefit even in unselected groups of stone formers, meaning it helped patients regardless of their specific metabolic profile.
Dosage and What to Expect
Most clinical studies used potassium-magnesium citrate formulations rather than standalone magnesium citrate supplements you’d find over the counter. In one study focused on correcting magnesium deficiency in stone formers, 300 mg of chelated magnesium daily for one month significantly increased urinary citrate excretion, from about 238 to 361 mg per day. While that’s a smaller boost than the combination formulations achieved, it still represents a clinically meaningful improvement.
If you’re buying magnesium citrate as a standalone supplement, the magnesium content per capsule or tablet varies widely by brand. Pay attention to elemental magnesium listed on the label rather than the total weight of the magnesium citrate compound, since those numbers differ substantially. Side effects in the clinical trials were generally limited to minor gastrointestinal complaints like loose stools or stomach discomfort. This is especially common at higher doses, since magnesium citrate is also sold as an osmotic laxative. Starting at a lower dose and increasing gradually can help your body adjust.
Who Should Be Cautious
Magnesium citrate is not appropriate for everyone. People with reduced kidney function face a real risk of magnesium building up in the blood because the kidneys can’t excrete it efficiently. Symptomatic hypermagnesemia, which can cause muscle weakness, low blood pressure, and in severe cases cardiac problems, is most often seen in elderly patients or those with chronic kidney disease who take magnesium-containing supplements or laxatives. Blood magnesium levels above about 1.2 mmol/L are considered a threshold where additional magnesium supplementation is discouraged.
If your kidney function is normal and you form calcium oxalate stones, magnesium citrate is generally well tolerated and supported by solid evidence. If you have any degree of chronic kidney disease, getting your magnesium levels checked before supplementing is important. The supplement also won’t help with every type of kidney stone. Struvite stones, cystine stones, and pure uric acid stones have different chemistry and require different approaches.
Magnesium Citrate vs. Other Citrate Salts
Potassium citrate is the most commonly prescribed citrate salt for stone prevention and has the largest body of evidence behind it. Potassium-magnesium citrate offers the added benefit of magnesium’s independent stone-inhibiting effects, and the one head-to-head comparison against placebo showed an 80% risk reduction. Sodium citrate is another option but carries a disadvantage: the sodium load can increase urinary calcium excretion, potentially working against the goal of stone prevention.
For people who form calcium oxalate stones and have low urinary citrate, the magnesium citrate combination addresses two problems simultaneously. It raises citrate levels to reduce crystallization, and it supplies magnesium to further compete with calcium for oxalate binding. Roughly a third of recurrent stone formers have been found to be magnesium deficient, so the supplement may be correcting a nutritional gap at the same time it provides pharmacological benefit.